newsfilter
← Latest News
GlobeNewswire·

Trevi Therapeutics Announces Upcoming June and July Event Schedule

TRVI
  • Trevi Therapeutics, Inc. (NASDAQ: TRVI) announced that senior management will attend three upcoming events in June & July 2026.
  • Representatives Jennifer Good & Farrell Simon will attend the BIO International Convention in San Diego from June 22-25, 2026.
  • Representatives David Hastings & Farrell Simon will attend the Leerink Partners Therapeutics Forum 2026 in Boston from July 14-15, 2026.
  • Representatives Jennifer Good & James Cassella will attend the ERS Cough Conference 2026 in London from July 15-17, 2026.
  • Trevi is developing Haduvio™ (oral nalbuphine extended-release) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), & refractory chronic cough (RCC).
  • Haduvio is the first investigational therapy to demonstrate a statistically-significant reduction in cough frequency across IPF-related chronic cough & RCC clinical trials.
  • The therapy functions as a kappa agonist & mu antagonist (KAMA) targeting opioid receptors involved in the cough reflex arc.
  • Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.
  • Approximately 140,000 U.S. patients have IPF, with two-thirds suffering from uncontrolled chronic cough.
  • Approximately 228,000 U.S. patients have non-IPF ILD, with 50-60% experiencing uncontrolled chronic cough.
  • Chronic cough can reach up to 1,500 occurrences per day, potentially increasing morbidity, mortality, & hospitalization risks.
  • RCC affects approximately 2-3 million U.S. patients & is defined as a persistent cough lasting over 8 weeks despite treatment for underlying conditions.
  • No FDA-approved therapies currently exist for chronic cough in IPF, non-IPF ILD, or RCC.
  • Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER, though safety & efficacy remain unevaluated by regulatory authorities.